CAPR
Capricor Therapeutics, Inc.
$22.25
+0.03 (+0.14%)
At close · Jul 8
Market Cap
$1.30B
Shares
57,911,893
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$22.25
Open$22.26
Day$21.41–23.03
52W$4.30–40.37
Avg vol 30d1.3M
Short int11.7M · 20.2% float · 13.7d
Short vol46%
Last earningsMay 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
−22%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−10%
trailing
YTD return
−23%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $23 — 50d above 200d
Institutional flow
Distributing
3 of 180 funds reported for Jun 30 · net -120 sh shares
Insider flow
Distributing
Net -$3.1M over 90 days · 100% sells
Short interest
Rising
20.20% of float · ▲ +5.7% MoM · 13.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
180 holders — near 3-yr high, broad support
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−97%
Y/Y
Free cash flow
$-72.7M
Balance sheet
$287.8M
net cash
Quant / Vol
risk profile
Volatility
383%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 11, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 12, 2026
Cash balance
· into Q4 2027
$279M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
−22%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $29 › 200d $23 — 50d above 200d
Institutional flow
Distributing
3 of 180 funds reported for Jun 30 · net -120 sh shares
Insider flow
Distributing
Net -$3.1M over 90 days · 100% sells
Short interest
Rising
20.20% of float · ▲ +5.7% MoM · 13.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
180 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $22 · 50%
52-wk high $40
vs 200-day avg -1%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash balance | 279M | Q1 2026 | — |
| Infusions administered (Deramiocel) | 800 | Q1 2026 | — |
| Patients enrolled across open-label extension studies | 90 | Q1 2026 | — |
| Cash, cash equivalents and marketable securities | $318.1M | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CAPR
this stock
Capricor Therapeutics, Inc.
|
$1.30B | -22.9% | -100.0% | — | 20.2% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CAPR | -7.6% | -15.0% | -10.3% | -7.6% | -22.9% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -7.4% | -15.8% | -17.7% | -7.4% | -32.2% |